Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer

NCT02283320 is registered in ClinicalTrials.gov with BIND Therapeutics as lead sponsor.

NCT NCT02283320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer
Lead sponsor
BIND Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
April 30, 2016
Enrollment
69 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

kras positive patients with non-small cell lung cancer, squamous cell non-small cell lung cancer